1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Sanjivani Paranteral Ltd.

Sanjivani Paranteral Ltd.

BBSE:SANJIVIN
151.20
INR
-9.20
(-5.74%)
6.22EPS
25.15P/E
1.90BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
268.31
225.1
195.51
54.59
30.24
41.3
27.15
29.07
30.38
35.25
45.95
59.19
55.95
62.23
Basic EPS, GAAP
2.7
-4.09
-24.82
-44.45
-89.95
-3.5
-2.9
1.67
4.85
4.51
5.28
6.89
5.56
6.15
Free Cash Flow per Basic Share
12.6
-2.64
-0.1
16.22
5.17
4.2
-0.3
0.17
7.84
3.59
-11.99
-15.27
-8.44
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.5
- -
Book Value per Share
59.35
54.5
29.67
-14.78
-89.55
-80.03
-82.93
-52.83
-7.58
-3.07
23.88
31.98
39.28
- -
Tangible Book Value per Share
59.35
54.5
29.67
-14.78
-89.55
-80.03
-82.93
-52.83
-7.58
-3.07
23.88
31.87
38
- -
Basic Weighted Avg Shares
6
6
6
6
6
6
6
8
10
10
12
12
12
12
Sales/Revenue/Turnover
1,583
1,328
1,153
322
178
244
160
247
304
352
537
696
683
746
Operating Margin (%)
5.64
2.94
-5.96
-47.43
-99.88
6.13
1.5
10.14
14.76
12.53
13.52
13.99
13.47
13.57
Depreciation Expense
10
14
14
12
12
12
11
9
9
9
9
6
12
17
Net Income, GAAP
16
-24
-146
-262
-531
-21
-17
14
48
45
62
81
68
74
Effective Tax Rate (%)
47.49
- -
- -
- -
- -
- -
- -
- -
0.66
8.75
18.58
21.81
28.73
28.42
Profit Margin (%)
1.01
-1.82
-12.7
-81.44
-297.44
-8.48
-10.67
5.74
15.95
12.8
11.48
11.64
9.94
9.89
Working Capital
158
231
86
-175
-632
-489
-516
-484
-142
-144
149
24
100
- -
LT Debt
55
48
124
70
45
81
80
53
27
8
10
53
86
- -
Total Equity
350
321
175
-87
-528
-472
-489
-449
-76
-31
279
399
508
- -
Return on Invested Capital (%)
1.72
- -
- -
- -
- -
- -
- -
- -
308.08
370.53
38.67
19.65
11.23
- -
Return on Capital (%)
5.84
- -
- -
- -
- -
- -
- -
- -
-2,309.63
-435.79
44.3
21.91
12.85
- -
Return on Common Equity (%)
4.66
-7.19
-58.98
- -
- -
- -
- -
- -
- -
- -
- -
24.58
15.74
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
57
- -
LT Borrowings
- -
86
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
12
12
Market Capitalization
2,844
1,631
1,900

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
364
- -
Cash, Cash Equivalents & STI
- -
13
- -
Accounts Receivable, Net
- -
154
- -
Inventories
- -
110
- -
Total Current Liabilities
- -
264
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
57
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-73.98%
-216.12%
27.51%
Free Cash Flow
-1,135.85%
922.18%
-42.61%
Net Income, GAAP
17.13%
57.27%
-16.2%
Sales/Revenue/Turnover
5.89%
23.8%
-1.86%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
164
181
173
182
696
2026
179
155
221
132
683
2027
238
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1.47
1.96
1.62
1.84
6.89
2026
1.46
1.33
2.21
0.49
5.56
2027
2.03
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
0.5
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ashwini Anamisharan Khemka
Full Time Employees
43
Sector
Health technology
Industry
Pharmaceuticals: major
Address
1202, B-Wing, O2 Business Commercial Park Mumbai MA India 400080
IPO Date
Jan 22, 1996
Website
sanjivani.co.in
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Sanjivani Paranteral Ltd Sanjivani Paranteral Ltd (SANJIVIN.BO), founded in 1994 and headquartered in Mumbai, India, operates as a WHO-GMP certified pharmaceutical manufacturer specializing in research-based, export-oriented production of high-quality parenteral and oral solid formulations; its core products encompass small volume injectables, sterile powder formulations, tablets, capsules, ointments/creams, nutraceuticals, and branded generics across therapeutic areas including central nervous system, cardiovascular, antibiotics, gastroenterology, anti-diabetics, anti-allergics, urology, anesthetics, anti-fungals, anti-depressants, muscle relaxants, and vitamin supplements. The company maintains two primary manufacturing facilities in Mumbai (Navi Mumbai) and Dehradun, India, with exports accounting for over 80% of revenue to more than 25 countries in regions such as Africa, the Middle East, CIS countries, Europe, and Latin America; it also caters to domestic markets through collaborations with partners like Merind, Lupin Laboratories, USV, Cadila Ltd., Alkem Ltd., and Ranbaxy. Recent developments include a joint venture with Hindustan Antibiotics Limited to produce intravenous formulations and IV sets in Pune, Maharashtra, commencing commercial operations in September 2025 at an expected capacity of 5 million IV fluid bottles and 1 million IV sets per month; a partnership with Aievia Healthcare s.r.o. in Prague, Czech Republic, launched in 2023 for European Union market entry; incorporation of subsidiary SPL Infusion Private Limited in February 2024 with 60% ownership to support infusion production; plans for a new high-grade antibiotics and life-saving injectables plant in Taloja, Maharashtra; and ongoing product development in infusion injectables, IV sets, pre-filled syringes, oncology, and hormones, alongside capacity enhancements and regulatory upgrades.